BioMerieux Free Cash Flow 2017-2023 | BMXMF
BioMerieux annual/quarterly free cash flow history and growth rate from 2017 to 2023. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- BioMerieux free cash flow for the quarter ending December 31, 2023 was , a year-over-year.
- BioMerieux free cash flow for the twelve months ending December 31, 2023 was , a year-over-year.
- BioMerieux annual free cash flow for 2023 was $0.123B, a 43.35% decline from 2022.
- BioMerieux annual free cash flow for 2022 was $0.217B, a 66.12% decline from 2021.
- BioMerieux annual free cash flow for 2021 was $0.64B, a 69.79% increase from 2020.
| BioMerieux Annual Free Cash Flow | |
|---|---|
| 2023 | 122.84 |
| 2022 | 216.83 |
| 2021 | 640.06 |
| 2020 | 376.96 |
| 2019 | 170.80 |
| 2018 | 195.46 |
| 2017 | 205.60 |
| 2016 | 119.40 |
| 2015 | |
| BioMerieux Quarterly Free Cash Flow | |
|---|---|
| 2023-12-31 | |
| 2022-12-31 | |
| 2022-06-30 | |
| 2021-12-31 | |
| 2021-06-30 | |
| 2020-12-31 | |
| 2019-12-31 | |
| 2019-06-30 | |
| 2018-12-31 | |
| 2018-06-30 | |
| 2017-12-31 | |
| 2017-06-30 | |
| 2016-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $12.753B | $3.977B |
| bioM?rieux S.A. designs, develops, manufactures and markets systems in the field of vitro diagnostics. The company provides diagnostic solutions which determine the source of disease and contamination. It also offers solutions for managing infectious diseases, cancers and cardiovascular diseases in clinical applications. The company provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing for the agri-food, cosmetics and pharmaceutical industries. bioM?rieux S.A. is based in Marcy L Etoile, France. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $96.018B | 11.91 |
| Cencora (COR) | United States | $46.162B | 17.64 |
| DiDi Global (DIDIY) | China | $23.816B | 0.00 |
| ICON (ICLR) | Ireland | $18.182B | 16.19 |
| Natera (NTRA) | United States | $15.356B | 0.00 |
| Avantor (AVTR) | United States | $15.184B | 22.76 |
| Revvity (RVTY) | United States | $14.929B | 26.14 |
| Viatris (VTRS) | United States | $13.870B | 4.23 |
| Solventum (SOLV) | United States | $12.515B | 0.00 |
| CochLear (CHEOY) | Australia | $12.315B | 0.00 |
| Medpace Holdings (MEDP) | United States | $9.932B | 27.98 |
| Charles River Laboratories (CRL) | United States | $9.343B | 17.66 |
| Sonic Healthcare (SKHHY) | Australia | $8.376B | 0.00 |
| Doximity (DOCS) | United States | $7.863B | 49.82 |
| HealthEquity (HQY) | United States | $7.539B | 40.92 |
| Bausch + Lomb (BLCO) | Canada | $7.221B | 33.62 |
| PACS (PACS) | United States | $6.544B | 0.00 |
| Life Times (LTH) | United States | $4.665B | 30.88 |
| Organon (OGN) | United States | $4.653B | 4.69 |
| Sotera Health (SHC) | United States | $4.492B | 22.66 |
| Surgery Partners (SGRY) | United States | $3.655B | 40.49 |
| BrightSpring Health Services (BTSG) | United States | $2.958B | 63.89 |
| Concentras Parent (CON) | United States | $2.542B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.527B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.482B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $2.349B | 88.43 |
| GeneDx Holdings (WGS) | United States | $2.094B | 0.00 |
| Premier (PINC) | United States | $2.032B | 9.14 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.922B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.586B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $1.402B | 7.04 |
| Progyny (PGNY) | United States | $1.354B | 23.81 |
| Pediatrix Medical (MD) | United States | $1.306B | 12.78 |
| Establishment Labs Holdings (ESTA) | $1.269B | 0.00 | |
| CareDx (CDNA) | United States | $1.194B | 0.00 |
| Agilon Health (AGL) | United States | $1.111B | 0.00 |
| Embecta (EMBC) | United States | $0.822B | 5.48 |
| InnovAge Holding (INNV) | United States | $0.803B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.790B | 0.00 |
| SBC Medicals (SBC) | United States | $0.707B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.505B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.470B | 0.00 |
| DocGo (DCGO) | United States | $0.371B | 13.96 |
| Enhabit (EHAB) | United States | $0.365B | 31.52 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.325B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.261B | 0.00 |
| ModivCare (MODV) | United States | $0.230B | 7.32 |
| Beauty Health (SKIN) | United States | $0.206B | 0.00 |
| Biodesix (BDSX) | United States | $0.189B | 0.00 |
| LifeMD (LFMD) | United States | $0.186B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.184B | 0.00 |
| MultiPlan (MPLN) | United States | $0.148B | 0.00 |
| Nutex Health (NUTX) | United States | $0.114B | 0.00 |
| So-Young (SY) | China | $0.089B | 21.53 |
| Harvard Apparatus Regenerative Technology (HRGN) | United States | $0.059B | 0.00 |
| OncoCyte (OCX) | United States | $0.051B | 0.00 |
| NeueHealth (NEUE) | United States | $0.042B | 1.69 |
| Co-Diagnostics (CODX) | United States | $0.039B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.037B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.034B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.029B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.025B | 0.00 |
| Oncology Institute (TOI) | United States | $0.023B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| XWELL (XWEL) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.007B | 0.00 | |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| KindlyMD (KDLY) | United States | $0.006B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |